2025. Spesolimab Improves Quality of Life in Generalized Pustular Psoriasis (GPP) as Measured by Proportion of Patients With Dermatology Life Quality Index (DLQI) Scores of 0 or 1 and Reduction in Pain Severity Over Time: Results From the EFFISAYIL® 2 Trial. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s652. DOI:https://doi.org/10.25251/fmm5fj59.